The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.

This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.

Inclusion Criteria:

Eligibility Criteria for objective #1:

• Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
• Patients who are undergoing a planned PET-CT scan at main campus of MSK.
• Patients must be ≥ 18 years old

Eligibility Criteria for objective #2:

• Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
• Patients with metastatic prostate or head and neck cancer.
• Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
• Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
• Patients must be ≥ 18 years old

Eligibility Criteria for objective #3:

• Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
• Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK.
• Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
• Patients must be ≥ 18 years old

Exclusion Criteria:

• Patients who suffer from claustrophobia.
• Women who are pregnant or breast-feeding.
• Patients < 18 years of age

Any MSKCC patients with histologically confirmed cancer, who will be scheduled to receive a planned PET-CT scan at the MSK main campus may be enrolled in this image evaluation and improvement study. Potential patients will be identified by a member of the patient's treatment team at MSKCC, who will introduce the study to them.

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.